Dishman Pharma to jointly develop API Poland based Polpharma
Dishman Pharmaceuticals & Chemicals Ltd has announced that Dishman Pharma - India and Polpharma - Poland have signed a cooperation and joint API development agreement.
Polpharma is in particularly a strong player in its home market and a leader in the Central and Eastern European markets and CIS countries with a turnover of ca 400 million US dollars.
Polpharma is also a CEE leader in the API sales with almost 90% of which in regulated markets including USA. Dishman group, a dedicated CRM player has Ca. 200 million US dollars turnover. Both Companies feel that this partnership will benefit mutually and pave the way for a stronger growth in coming years.
The Dishman Pharma stock was trading at Rs.96.65, up by Rs.0.65 or 0.68%. The stock hit an intraday high of Rs.106 and low of Rs.95.
The total traded quantity was 43822 compared to 2 week average of 27270.
